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Abstract
Objective: Among women with rheumatoid arthritis (RA) we aimed to assess the effect of optimal 
management of pregnancy, on a composite outcome of miscarriage and complicated birth. Methods: Data 
were extracted from healthcare databases of the Lombardy Region, Italy (2004–2013), as a part of the 
RECord-linkage On Rheumatic Diseases Study. Analyses included women with RA identified through 
copayment exemption code (ICD9-CM code 714.0) and controls from the general population aged 
between 18 and 50. Seven healthcare quality indicators (HCQI) were constructed and summarized in 3 
pathways indicators: A) diagnostic; B) therapeutic; C) and prenatal follow-up. The groups of complicated 
birth or miscarriage identified the adverse pregnancy outcome (APO). The relationship between HCQI and 
APO was analysed using logistic models and the results presented as odds ratios (OR) and 95% confidence 
intervals (95%CI). Results: The study cohort included the first pregnancy observed in 443 patients with RA 
compared with 6097 women belonging to the general population. In RA population, patients who 
followed the ideal pathway had a reduced risk of overall APO with an OR=0.60 (95%CI 0.39, 0.94) and of 
miscarriage/perinatal death with an OR=0.40 (95%CI 0.24, 0.69) compared to those who did not. 
Compared with the general population, patients with RA who met all HCQI during pregnancy displayed a 
risk of APO with an OR=0.92 (95%CI 0.61, 1.38) and miscarriage/perinatal death with an OR=0.77 (95%CI 
0.47,1.29). Conclusions: The adherence to the ideal clinical pathway in women with RA restored the risk of 
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Significance and Innovations 
 Women with RA who followed an ideal pathway i.e., stratification of pre-conceptional obstetric 
risk, modulation of therapy, and prenatal rheumatological follow-up had a reduced risk of 
complicated birth or miscarriage compared to women with RA who did not follow the ideal 
pathway. 
 In RA, the optimal management of pregnancy restores the risk of adverse pregnancy outcome to 
that expected for the general population. 
 This study proposed, for the first time, seven healthcare quality indicators that need to be 
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Introduction
The management of pregnancy in women with Rheumatoid Arthritis (RA) has substantially changed in the 
past few decades, along with the milestones in RA treatment such as biologic and targeted synthetic 
agents, and treat-to-target strategies  (1). With the improvement in the management of RA, patients with 
severe disease have been able to reach remission more frequently and live normal lives, including starting 
a family. As a consequence, the paradigm that “RA spontaneously improves during pregnancy” has been 
defied over years, as nearly half of RA pregnant patients can have disease flares  (2). Therefore, it has 
become critical to provide a tool for risk stratification and develop uniform management plans to improve 
favourable pregnancy outcomes among women with RA. Preconception counselling should include 
evaluation of maternal disease activity, modification of treatment, and assessment of general obstetric 
risk factors as performed in routine obstetric care  (3). Patients should be informed about specific wash-
out periods for teratogenic medications such as methotrexate (MTX) and leflunomide (LFN) and, 
conversely, about the fact that several anti-rheumatic drugs are appropriate for use during pregnancy and 
lactation   (4).
This approach to women of childbearing age with RA could be considered as an “ideal” management 
pathway, however, in the literature, neither data explored the impact of this pathway on pregnancy 
outcomes nor guidelines specifically aimed at pregnancy management in RA. Whereas it would be suitable 
to have a systematic approach to the issue of pregnancy in RA, we have identified seven healthcare 
quality indicators (HCQI) grouped in A) diagnostic; B) therapeutic; C) and prenatal follow-up pathways, 
partly adopted from recommendations developed in other rheumatic conditions  (5). Evidence support 
that RA patients with an active disease have significantly less chance for spontaneous improvement 
during pregnancy and are at risk for adverse pregnancy outcome (APO) making appropriate to consider 
instrumental (e.g. musculoskeletal imaging) and laboratory assessments (e.g. C-reactive protein test) as 
part of pre-conceptional risk stratification in patient with RA  (6,7). In addition, in patients planning a 
pregnancy, expert’s opinion supports the usefulness of a more extensive laboratory assessment including 
acknowledged potential risk factors for pregnancy complications, firstly anti-Ro/-La antibodies and 
antiphospholipid (aPL) antibodies (8).  
To date, robust data on pregnancy outcomes are very desirable, especially when exploring the impact of 
different therapeutic approaches or clinical pathways. For this purpose, data from administrative 
healthcare databases (AHD) are useful due to their virtually complete coverage of the general population. 
This study aimed to evaluate the impact of adherence to A) diagnostic; B) therapeutic; C) and prenatal 









belonging to the general population and with women with RA who did not adhere, in an unselected 
population-based dataset. 
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Patients and Methods
Study design and setting 
This is a retrospective observational study on the RECord-linkage On Rheumatic Diseases (RECORD) 
dataset, including data from AHD of the Lombardy region (>10,000,000 inhabitants), Italy. In detail, the 
design of the RECORD study includes a database population derived from 115,684 records of potentially 
RA individuals and 462,736 non-RA individuals matched by sex, age and province of origin (4 non-RA cases 
for each case of potential RA). As elsewhere described, we developed and validated an algorithm that 
identified 70,061 'true' cases of RA matched by sex and age with 280,244 non-RA cases within the original 
population of 462,736 non-RA cases through copayment exemption code 006.714.0 and based on its 
demonstrated high specificity (96.39%) and good sensitivity (77.08%) for RA  (9). Access to data was 
granted by the General Directorate of Health for the purpose of the RECORD study, a project promoted by 
the Italian Society for Rheumatology aiming to set up a national surveillance system to monitor the health 
burden of rheumatic diseases in Italy using AHD. The protocol was approved by the ethical committee of 
the Pavia University Hospital. Data included were retrieved between 1 January 2004 and 31 December 
2013. 
Participants 
From RECORD dataset, we extracted data of female patients with RA and controls women aged between 
18 and 50  (9). Only data for the first pregnancy observed both in patients after the time of diagnosis of 
RA and in control cases were analyzed. Data included demographics (birthdate), redeemed prescriptions 
(Anatomic Therapeutic Chemical code, date of drug delivery, quantity), disease certification (code and 
date), outpatient visits (code and date) and hospital discharge forms including information on the date of 
delivery or miscarriage. The time of conception has been approximated from the date of delivery or 
miscarriage. Exposure to glucocorticoids (GCs), aspirin, low molecular weight heparin (LMWH), biological 
synthetic disease modifying drugs (bDMARDs), conventional synthetic DMARDs (csDMARDs) clustered in 
not recommended (MTX and LFN) and appropriate (cyclosporine A; hydroxychloroquine, HCQ; 
sulphasalazine; azathioprine). Concomitant comorbidities including the Charlson comorbidity index, 
thyroid diseases, chronic kidney failure, pre-gestational diabetes and hypertension were recorded as 
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Seven healthcare quality indicators (HCQI) were constructed based on fulfillment of the following seven 
criteria: 1) having at least one  blood lab tests (including erythrocyte sedimentation rate and/or C-reactive 
protein test) performed within 18 months before conceiving and the date of delivery or miscarriage); 2) 
pre-conception musculoskeletal imaging (including x-ray or ultrasound examinations of hands and feet 
performed within 18 months before conception and date of delivery or miscarriage) ; 3) pre-pregnancy 
aPL tests (at least one test performed within 18 months prior to conception, and the date of delivery or 
miscarriage); 4) ANA test and anti-ENA (anti-Ro/SSA) test (at least one test prescribed within 18 months 
prior to conception, and the date of delivery or miscarriage) ; 5) no exposure or wash-out from 
teratogenic drugs (MTX/LEF) indicated by the absence of redemption between 6 months before pre-
conception and date of delivery or miscarriage; 6) no exposure to biological drugs (no medical 
prescriptions for abatacept, tocilizumab, rituximab, anakinra, certolizumab, etanercept, infliximab, 
adalimumab, golimumab between the presumed date of conception and date of delivery or miscarriage 
(at the time the study was conducted targeted synthetic DMARDs were not available in Italy and exposure 
to these drugs was not taken into account); 7) rheumatologic monitoring and follow-up via outpatient 
visits (at least one outpatient visit at the rheumatology department for women with RA). The 7 indicators 
were summarized in 3 main pathways indicators: A) diagnostic pathway composed by 1) blood lab tests; 
2) musculoskeletal imaging; 3) aPL antibodies tests, 4) ANA and anti-ENA tests); B) therapeutic pathway 
based on 5) no exposure or wash-out from MTX/LEF or 6) no exposure to biological drugs; C) prenatal 
follow-up pathway 7) consisting of at least one rheumatological visit. The concomitant presence of all the 
3 pathways indicators (A+B+C) defined the ideal clinical pathway. 
Statistical methods
The pregnancy outcome was defined on the basis of the Disease-Related Groups (DRG, version 24) of 
complicated birth, pregnancy losses (miscarriage) or perinatal death collectively defined as APO codes 
(370: cesarean section due to complications, 372: vaginal delivery with complications, 374 and 375: 
vaginal delivery with complications requiring surgical intervention, 378: ectopic pregnancy, 379: 
threatened miscarriage; 380: spontaneous miscarriage, 381: spontaneous miscarriage requiring surgical 
intervention) and ICD9-CM codes (V271-277: perinatal death)  (15). Sub-analysis on miscarriage and 
perinatal death (DRG 380-381, V271-273-274-276-277) was also performed. Conception date was 
estimated 42 days before the date of miscarriage for DRG 378-379 and 380 and 84 days before the date of 
miscarriage for DRG 381. 
The relationship between HCQI and outcome variables was analyzed using logistic models crude and 
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patients versus the general population; adjusting for age, Charlson comorbidity index and thyroid diseases 
comparing women with RA who followed the ideal pathway versus women that did not. The results are 
presented as odds ratios (OR) and 95% confidence intervals (95% CI). All the analyses were performed 
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Results
The study cohort included the first pregnancy observed in 443 patients with RA compared with 6097 
control women belonging to the general population. Table 1 summarizes the demographic and 
therapeutic features of our cohort. The mean maternal age for all sampled mothers was 34 years (RA 
interquartile range 31-37, general population interquartile range 30-37). RA patients had a significantly 
higher frequency of thyroid diseases, overall APO and miscarriage/perinatal death as compared to the 
general population. Patients with RA adherent to the ideal clinical pathway were similar to non-adherent 
in socio-demographic and disease characteristics (Table 1). Overall, compared to women with RA who did 
not adhere to the ideal clinical pathway, RA patients in the ideal pathway were more exposed to 
treatment (no treatment in 56 patients in ideal pathway (39.7%) versus 199 cases not in ideal pathway 
(65.9%), p <0.001), including GCs (57 RA patients (40.4%) in ideal pathway versus 61 (20.2%) for those not 
in ideal pathway) and HCQ (58 patients (41.1%) in ideal pathway versus 44 (14.6%) not in ideal pathway, 
p<0.001) (Table 1). 
Patients with RA who followed the ideal clinical pathway had a reduced risk of overall APO with an 
adjusted OR = 0.6 (95%CI 0.39, 0.94) and of miscarriage/perinatal death with an adjusted OR = 0.4 (95%CI 
0.24, 0.69) compared to women with RA who did not adhere (Table 2). Among the three pathways (A, B, 
C), the multivariate analysis identified the therapeutic pathway as the main factor associated with overall 
APO with an adjusted OR = 0.28 (95% CI 0.14-0.55) and with miscarriage/perinatal death with an adjusted 
OR = 0.22 (95%CI 0.11-0.46). Analysing the associations between individual HCQI and APO, in the 
diagnostic pathway, aPL tests had an adjusted OR = 0.56 (95%CI 0.37, 0.85) and ANA or anti-ENA tests had 
an adjusted OR = 0.64 (95%CI 0.42, 0.96); in therapeutic pathway no exposure or washout of MTX/LEF had 
an adjusted OR = 0.22 (95%CI 0.11,0.46) (Table 2). Only two patients had not withdrawn the ongoing 
treatment with bDMARDs, making a reliable estimation of OR for this item not feasible (Table 2). 
Compared with the general population, RA patients who met diagnostic, therapeutic and prenatal follow-
up pathways indicators displayed a risk of APO with an adjusted OR = 0.92 (95%CI 0.61, 1.38) and of 
miscarriage/perinatal death with an adjusted OR = 0.77 (95%CI  0.47,1.29) (Table 3). Additional sensitivity 
analysis performed excluding ectopic pregnancy, threatened miscarriage and twin pregnancies (DRG D78, 
DRG 279, V272-273-274-276-277) gave similar results (supplementary Tables 1-4). 
Further exploratory analyses evaluated the effect of common anti-rheumatic drugs used during pregnancy 
and preventative treatments, such as aspirin and LMWH, on outcomes of interest in patients with RA 
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1.40 (95%CI 1.09, 1.81; p=0.014), the RR for miscarriage and perinatal death in LMWH users was = 0.20 
(95%CI 0.03, 1.33; p=0.05), while the use of aspirin had no influence on APO with a RR = 0.99 (95%CI 0.54, 
1.82; p=1) and on miscarriage/perinatal death with a RR = 0.46 (0.12, 1.67; p= 0.25). No differences were 
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Discussion
This study based on AHD data demonstrated that the optimal management of pregnancy defined as “ideal 
clinical pathway” in women with RA was associated with a significantly reduced risk of APO restoring it to 
that expected for the general population. 
Overall, we found an increased rate of APO and miscarriage/perinatal death in RA patients as compared 
to the general population (APO = 157 cases in RA patients versus 1809 cases in the general population, p 
0.012;  miscarriage/perinatal death = 115 cases versus 1360 cases in the general population, p 0.044). 
Nearly one-third of pregnant patients (157 cases, 35.4%) with RA experienced APO and one fourth (155 
cases, 26%) had a pregnancy loss or miscarriage/perinatal death. Our data agree with some previous 
studies conducted using AHD. Lin et al. demonstrated that after adjusting for potential confounders, 
mothers with RA were (OR) 1.47 (95%CI 1.22, 1.78), 1.20 (95%CI 1.05, 1.38), 2.22 (95%CI 1.59, 3.11) and 
1.19 (95%CI 1.07 to 1.31) time more likely than unaffected mothers to experience low birth weight, small 
for gestation age infants, preeclampsia  and caesarean sections (7). Similarly, a previous study reported 
firstborn children of women diagnosed as having chronic inflammatory arthritis were often preterm and 
they had higher perinatal mortality with an OR = 3.26 (95%CI 1.04, 10.24) (16). 
We found that between the three main pathways indicators of the ideal clinical pathway (stratification of 
pre-conceptional obstetric risk, modulation of therapy, and prenatal rheumatological follow-up) “the ideal 
therapeutic pathway” comprising no exposure or wash-out from MTX/LEF and no exposure to biological 
drugs, conferred a significantly reduced odds of APO and miscarriage/perinatal death. If LEF and MTX are 
not recommended in women planning and during pregnancy and this justifies the choice as HCQI, the 
item related to bDMARDs discontinuation deserves an additional thought. We identified the HCQI “no 
exposure to biological DMARDs” as a surrogate marker of maternal disease activity and not because of 
the assumption of teratogenicity/toxicity of these treatments. In our study only two patients continued 
bDMARDs , besides, in the period covered by RECORD study (1 January 2004 - 31 December 2013) there 
were sparse data on bDMARDs use in pregnancy, as well as the European League Against Rheumatism 
(EULAR) and the British Society for Rheumatology had not yet published guidelines for the prescription of 
pregnancy-compatible medications. This reflects the attitude at the time the study was conducted, but it 
is likely that the scenario will change as the use of biologic bDMARDs during pregnancy will consolidate  
(1). 
The significant association between the ideal therapeutic pathway with the outcomes of the study 
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reinforces the importance of adjustment of therapy for RA before conception and throughout pregnancy, 
because medication use could affect pregnancy course not only influencing maternal disease activity but 
also the gestational outcome. In our study, compared to RA patients not adherent to the ideal pathway, 
adherent cases were significantly more exposed to treatment, including HCQ and glucocorticoids. The use 
of steroids during pregnancy has been proved to be an independent risk factor for preterm delivery in 
women with RA when used at high doses (17,18). Although this is a study conducted on administrative 
data, we can hypothesize that exposure to therapy represents a marker of high RA disease activity and 
severity. In our setting, it is possible that the more active the disease the greater the probability of being 
included in the ideal clinical pathway, but in any case, this resulted in a lower OR of APO and 
miscarriage/perinatal death. If the diagnostic and prenatal follow-up pathways appear to have a marginal 
effect in our study, nevertheless, there might also be a residual confounding given that patients properly 
treated could have appropriate stratification of pre-conceptional obstetric risk and timely prenatal 
rheumatological follow-up.
Analysing individual HCQI in women with RA, we observed that, especially screening for aPL antibodies, 
ANA and anti-ENA were associated with a lower OR of APO and miscarriage/perinatal death. Notably, aPL 
antibodies occur in RA patients with an estimated prevalence up to 30%, more than expected in the 
general population, and the presence of significant and persistently positive titers increases the risk of 
APO including unexplained spontaneous miscarriage, premature births, preeclampsia, placental 
insufficiency with growth restriction, and prematurity, all potential complications of pregnancy that have 
been described in RA (19). In this view, we have incorporated aPL tests as part of diagnostic HCQI and as 
advised by EULAR recommendation for the prevention and management of aPL syndrome in adults (20). 
This study might suggest the value of searching for aPL antibodies in RA patients wishing for a pregnancy. 
In fact, despite the absence of formal recommendation or validated HCQI focused on stratification of pre-
conceptional obstetric risk in patients with RA, we started from the basic and universally accepted 
assumption that aPL antibodies are pathogenic autoantibodies and therefore recognized risk factors for 
APO (20). Also, RA pregnancy may have an increased risk of APO, this combined with the increased 
prevalence of aPL antibodies in RA itself, could have a synergistic effect between RA and aPL antibodies in 
the determinism of APO  (21). RA and aPL antibodies could be two distinct factors that must be 
individually profiled and the exclusion of one of them it would imply a sub-optimal risk stratification 
(5,20,21). This is undoubtedly a speculative conclusion, just supported by expert’s opinion, but our study 
could be the first to give indirect evidence of the impact of diagnostic pathway indicators on APO that 
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To our knowledge, this study demonstrates for the first time that adherence to the ideal clinical pathway 
and especially the modulation of therapy such as discontinuation of contra-indicated medications such as 
MTX and LFN associated with a reduced risk of complicated birth or miscarriage in women with RA. This 
data was confirmed after adjusting for specific comorbidities that can interfere with gestational outcome, 
such as thyroid diseases, more prevalent and common in patients with RA compared to the general 
population. The strength of our study lies in the advantage of providing population-based samples 
representative of the target population, allowing generalizability of findings. This data source avoids 
potential referral bias reported from multidisciplinary pregnancy clinics where cohorts of subset of 
patients are offered integrated management of pregnancy that could not be generalizable to the general 
rheumatic disease population  (22). 
We acknowledge that our study has limitations which are intrinsic in the administrative data. First, 
uncomplicated pregnancy losses occurred before 15 weeks did not require hospitalization and may not 
even be recognized  (22). Furthermore, the first pregnancy during the period of data captured is not 
necessarily the first pregnancy for that woman as enrolment periods in health insurance do not cover the 
entire reproductive history. Our approach based on AHD did not provide variables including lifestyle 
(maternal socioeconomic status, smoking, alcohol or body max index), results of laboratory exams and 
variables on disease activity, although we considered the use of glucocorticoids as proxies of more active 
disease, as shown in previous works (9,10). In our study only two patients were receiving bDMARDs 
during pregnancy, in fact, at the time the data were extracted, it was common practice to stop bDMARDs 
at positive pregnancy index  (23). An additional limitation is the lack of data about the new-born (birth 
weight, length and head circumference, neonatal adverse events). Ultimately, we could not account for all 
possible confounding factors, and some residuals confounding intrinsic to observational studies may still 
modify the risk of APO estimation in our cohort.  
The concept of preconception counselling and risk stratification, and multidisciplinary management 
during pregnancy has gained greater importance in the field of Rheumatology though to date many 
women struggle to find adequate counselling on reproductive issues to guide them on pregnancy 
planning, lactation, and early parenting in relation to their chronic condition  (3,24)  In conclusion, our 
findings suggest the adherence to an ideal clinical pathway should be strived for as much as possible in 
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Table 1. Characteristics and comparison of women with RA and general population and patients with RA adherents 






















Pregnancies, n (%) 443 (100) 6097 (100) 1 141 (100) 302 (100) 1
Age at conception - Median (IQR) 34 (31-37) 34 (30-37) 0.846 34 (31-37) 34 (30-37) 0.092
Disease duration at conception (years) - 
Median (IQR)
3.8 (1.8-6.2) N.A. --- 3.8 (1.7-6.0) 3.9 (1.9-6.3) 0.715
Charlson Index - Mean (SD) 1.1 (0.4) 0.1 (0.4) <0.001 1.1 (0.6) 1.0 (0.2) 0.120
Charlson Index - Mean (SD)§ 0.1 (0.4) 0.1 (0.4) 0.544 0.1 (0.6) 0 (0.2) 0.120
Specific comorbidities
Thyroid diseases, n (%) 24 (5.4) 145 (2.4) <0.001 5 (3.5) 19 (6.3) 0.335
Hypertension, n (%) 5 (1.1) 39 (0.6) 0.22 2 (1.4) 3 (1) 0.655
Chronic kidney failure, n (%) 0 (0) 1 (0) 1 0 (0) 0 (0) 1
Pre-pregnancy diabetes mellitus, n (%) 13 (2.9) 172 (2.8) 1 8 (5.7) 5 (1.7) 0.031
Treatment 
Glucocorticoids, n (%) 118 (26.6) 0 (0) --- 57 (40.4) 61 (20.2) <0.001
Hydroxychloroquine, n (%) 102 (23) 0 (0) --- 58 (41.1) 44 (14.6) <0.001
Aspirin, n (%) 20 (4.5) 0 (0) --- 12 (8.5) 8 (2.6) 0.012
Low molecular weight heparin, n(%) 20 (4.5) 0 (0) --- 9 (6.4) 11 (3.6) 0.294
Allowed csDMARDs, n (%) 48 (10.8) 0 (0) --- 21 (14.9) 27 (8.9) 0.087
No treatment, n (%)* 255 (57.6) 0 (0) --- 56 (39.7) 199 (65.9) <0.001
«Ideal pathway», n (%) 141 (31.8) N.A. --- --- --- ---
Ideal diagnostic pathway, n (%) 414 (93.5) N.A. --- --- --- ---
Ideal therapeutic pathway, n (%) 403 (91) N.A. --- --- --- ---
Ideal prenatal follow-up pathway, n (%) 172 (38.8) N.A. --- --- --- ---
Overall APO, n (%) 157 (35.4) 1809 (29.7) 0.012 --- --- ---









List of abbreviations: RA, Rheumatoid Arthritis; IQR, interquartile range; csDMARDs, conventional synthetic disease modifying 
antirheumatic drugs; APO, adverse pregnancy outcome. § Charlson Index calculated excluding rheumatic disease; *no treatment 
among glucocorticoids, hydroxychloroquine and allowed csDMARds. 
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Table 2. Odds ratio of overall APO, miscarriage and perinatal death in patients with RA who followed 
healthcare quality indicators compared to women with RA who did not (reference). 
 







1) Diagnostic pathway 1.05 (0.46-2.38) 0.84 (0.36-1.98)
N° pts adherent/not adherent, 414/29 147/10 106/9
Blood chemistry tests 0.99 (0.47-2.11) 0.78 (0.36-1.70)
N° pts adherent/not adherent, 409/34 145/12 104/11
Imaging 1.09 (0.72-1.65) 1.14 (0.72-1.81)
N° pts adherent/not adherent, 163/280 60/97 45/70
Antiphospholipid antibody tests 0.56 (0.37-0.85) 0.34 (0.20-0.56)
N° pts adherent/not adherent, 188/255 52/105 27/88
ANA or anti-ENA tests 0.64 (0.42-0.96) 0.43 (0.27-0.68)
N° pts adherent/not adherent,263/180 80/77 48/68
2) Therapeutic pathway 0.28 (0.14-0.55) 0.22 (0.11-0.46)
N° pts adherent/not adherent, 403/40 132/25 94/21
No exposure or washout of MTX/LEF 0.31 (0.15-0.62) 0.22 (0.11-0.46)
N° pts adherent/not adherent, 405/38 134/23 94/21
No exposure to biological DMARDs Not estimable Not estimable
N° pts adherent/not adherent, 441/2 155/2 115/0
3) Prenatal follow-up pathway    0.85 (0.56-1.28)   0.65 (0.40-1.04)
N° pts adherent/not adherent, 172/271 59/98 37/78
Rheumatological visit (at least one) 0.85 (0.56-1.28) 0.65 (0.40-1.04)
N° pts adherent/not adherent, 172/271 59/98 37/78
Ideal pathway 0.6 (0.39-0.94) 0.4 (0.24-0.69)
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Table 3. Odds ratio of overall APO, miscarriage and perinatal death in patients with RA who followed or 





General population Ref Ref
RA patients in ideal pathway 0.92 (0.61-1.38) 0.77 (0.47-1.29)
RA patients not in ideal pathway 1.5 (1.13-2) 1.84 (1.33-2.55)
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